Engineers Gate Manager LP lifted its position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Free Report) by 334.3% during the second quarter, HoldingsChannel reports. The firm owned 60,327 shares of the company’s stock after buying an additional 46,435 shares during the quarter. Engineers Gate Manager LP’s holdings in Immunocore were worth $1,915,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in IMCR. Braidwell LP acquired a new stake in Immunocore during the 2nd quarter worth $16,552,000. Armistice Capital LLC grew its stake in Immunocore by 33.3% in the fourth quarter. Armistice Capital LLC now owns 1,098,000 shares of the company’s stock valued at $38,112,000 after acquiring an additional 274,000 shares during the period. Fiera Capital Corp increased its holdings in shares of Immunocore by 31.4% in the fourth quarter. Fiera Capital Corp now owns 1,044,831 shares of the company’s stock worth $36,266,000 after acquiring an additional 249,674 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Immunocore by 30.9% in the first quarter. Janus Henderson Group PLC now owns 594,712 shares of the company’s stock worth $17,919,000 after acquiring an additional 140,308 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB raised its position in shares of Immunocore by 442.0% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 153,278 shares of the company’s stock worth $5,320,000 after purchasing an additional 125,000 shares during the period. Institutional investors own 84.50% of the company’s stock.
Wall Street Analyst Weigh In
IMCR has been the subject of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. Wall Street Zen lowered shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Morgan Stanley set a $43.00 price target on Immunocore in a research note on Friday, August 7th. JPMorgan Chase & Co. began coverage on Immunocore in a report on Friday, August 21st. They issued an “overweight” rating and a $50.00 price target on the stock. Finally, Mizuho increased their price objective on Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $56.38.
Immunocore Trading Down 2.1%
Immunocore stock opened at $31.77 on Wednesday. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -85.86 and a beta of 0.74. The firm has a 50-day moving average of $34.74 and a 200-day moving average of $31.80. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.47 and a quick ratio of 4.44. Immunocore Holdings PLC Sponsored ADR has a one year low of $27.56 and a one year high of $40.71.
Immunocore (NASDAQ:IMCR – Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%. On average, equities analysts expect that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current fiscal year.
Immunocore Profile
Immunocore Holdings plc is a biotechnology company that develops T-cell receptor (TCR) therapies designed to direct the immune system against cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-related peptides presented on the surface of cells and recruit T cells to destroy targeted cells.
The company’s lead product is KIMMTRAK (tebentafusp-tebn), an ImmTAC therapy approved in the United States, European Union and other markets for the treatment of unresectable or metastatic uveal melanoma in certain patients.
Read More
- Five stocks we like better than Immunocore
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Want to see what other hedge funds are holding IMCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Free Report).
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
